Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Values of Three Different Preoperative Regimens in Comprehensive Treatment For Young Patients with Stage Ib2 Cervical Cancer

  • Zhao, Yi-Bing (Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute) ;
  • Wang, Jin-Hua (Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute) ;
  • Chen, Xiao-Xiang (Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute) ;
  • Wu, Yu-Zhong (Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute) ;
  • Wu, Qiang (Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To compare the clinical efficacy of concurrent chemoradiotherapy, neoadjuvant chemotherapy, and intracavity brachytherapy in comprehensive treatment for young patients with stage Ib2 cervical cancer. Methods: One hundred and twelve young patients with stage Ib2 cervical cancer were enrolled retrospectively in our hospital from January 2003 to June 2005. They were categorized into three groups according to preoperative regimens, including the concurrent chemoradiotherapy group (Group 1, n=38), the neoadjuvant chemotherapy (Group 2, n=49), and the intracavity brachytherapy group (Group 3, n=25). Radical hysterectomy was performed following these regimens. Chemotherapy and radiotherapy were given according to pelvic lymph node metastasis, deep cervical stromal invasion, intravascular cancer emboli, histological grading, vaginal stump and positive surgical margin. Results: The cancer disappearance and superficial muscle invasion rates were statistically significantly better in the concurrent chemoradiotherapy group than in the other two groups (P<0.01). No statistically significant difference was noted in the deep muscle invasion rate, surgical time and intraoperative blood loss among three groups, but significantly more postoperative complications occurred in the concurrent chemoradiotherapy group. The 2-year pelvic recurrence was statistically significantly lower in the concurrent chemoradiotherapy group compared to other two groups, while the 5-year survival was higher. Conclusion: Concurrent chemoradiotherapy is efficacious for young patients with stage Ib2 cervical cancer.

Keywords

References

  1. Bae JH, Lee SJ, Lee A, et al (2008). Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer. Gynecol Oncol, 111, 444-8. https://doi.org/10.1016/j.ygyno.2008.07.034
  2. Choi CH, Kim TJ, Lee JW, et al (2007). Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol, 104, 64-9. https://doi.org/10.1016/j.ygyno.2006.07.006
  3. Darus CJ, Callahan MB, Nguyen QN, et al (2008). Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer, 18, 730-5. https://doi.org/10.1111/j.1525-1438.2007.01095.x
  4. Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol, 22, 872-80. https://doi.org/10.1200/JCO.2004.07.197
  5. Eddy GL, Bundy BN, Creasman WT, et al (2007). Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: A phase III trial of the gynecologic oncology group. Gynecol Oncol, 106, 362-9. https://doi.org/10.1016/j.ygyno.2007.04.007
  6. Ferrandina G, Distefano M, Ludovisi M, et al (2007). Lymph node involvement in locally advanced cervical cancer patients administered preoperative chemoradiation versus chemotherapy. Ann Surg Oncol, 14, 1129-35. https://doi.org/10.1245/s10434-006-9252-0
  7. Ferrandina G, Margariti PA, Smaniotto D, et al (2010). Longterm analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol, 119, 404-10. https://doi.org/10.1016/j.ygyno.2010.08.004
  8. Goksedef BPC, Kunos C, Belinson JL, Rose PG (2009). Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB(2) cervical carcinoma. Am J Obstet Gynecol, 200, 175e1-e5.
  9. Kuzuya K (2004). Chemoradiotherapy for uterine cancer: current status and perspectives. Int J Clin Oncol, 9, 458-70. https://doi.org/10.1007/s10147-004-0452-y
  10. Mariagrazia D, Anna F, Gabriella F, et al (2005). Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications. Gynecol Oncol, 99, S166-70. https://doi.org/10.1016/j.ygyno.2005.07.074
  11. Pearcey R, Miao Q, Kong W, Zhang-Salomons J, Mackillop WJ (2007). Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: Results of a population-based cohort study. J Clin Oncol, 25, 2383-8. https://doi.org/10.1200/JCO.2006.09.1926
  12. Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A gynecologic oncology group study. J Clin Oncol, 25, 2804-10. https://doi.org/10.1200/JCO.2006.09.4532
  13. Ryu HS, Kang SB, Kim KT, et al (2007). Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer, 17, 132-6. https://doi.org/10.1111/j.1525-1438.2007.00803.x
  14. Stehman FB, Ali S, Keys HM, et al (2007). Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol, 197, 503.e1-6. https://doi.org/10.1016/j.ajog.2007.08.003
  15. Tan LT, Zahra M (2008). Long-term survival and late toxicity after chemoradiotherapy for cervical cancer - The Addenbrooke's experience. Clin Oncol, 20, 358-64. https://doi.org/10.1016/j.clon.2008.03.001

Cited by

  1. Comparison of Clinical Efficacy of Three Different Neoadjuvant Approaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with Stage Ib2 and IIa2 Cervical Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2377
  2. Vaginal Dose, Toxicity and Sexual Outcomes in Patients of Cervical Cancer Undergoing Image Based Brachytherapy vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3619
  3. Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer vol.11, pp.11, 2016, https://doi.org/10.1371/journal.pone.0166612
  4. Genetic susceptibility in cervical cancer: From bench to bedside vol.233, pp.3, 2017, https://doi.org/10.1002/jcp.26019
  5. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205 vol.39, pp.7, 2017, https://doi.org/10.1177/1010428317711315
  6. The Progress of Methylation Regulation in Gene Expression of Cervical Cancer vol.2018, pp.2314-4378, 2018, https://doi.org/10.1155/2018/8260652